Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

• Published in: JTO clinical and research reports Vol. 2; no. 1; p. 100108
• Main Authors: Ou, Sai-Hong Ignatius, Fujiwara, Yutaka, Shaw, Alice T., Yamamoto, Noboru, Nakagawa, Kazuhiko, Fan, Frank, Hao, Yuki, Gao, Yanfei, Jänne, Pasi A., Seto, Takashi
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2021; Elsevier
• Subjects: AB-106; Brief Report; Crizotinib resistance; DS-6051b; Pooled analysis; ROS1 G2032R; ROS1+ NSCLC; Taletrectinib; DS-6051b; Taletrectinib; Pooled analysis; ROS1+ NSCLC; ROS1 G2032R; AB-106; Crizotinib resistance

Taletrectinib (AB-106/DS-6051b) is an oral, potent selective ROS1 and pan-NTRK tyrosine kinase inhibitor (TKI). Preclinically, taletrectinib has activity against ROS1 G2032R solvent-front mutation. Patients with ROS1+ NSCLC enrolled into two phase 1 studies conducted in United States (U101, NCT02279...